Taken together, these observations indicate that dual targeting of both bulk tumor cell proliferation and cancer stemness by this combination therapy could lead to more durable treatment responses and improved clinical outcomes, particularly for aggressive and therapy-resistant HER2+ breast cancer subtypes. Here, ERBB2 is linked to breast cancer.